Novel flufenamic acid analogues as inhibitors of androgen receptor mediated transcription.

No abstract is available for this paper.

• Publication year

  2009

• Venue

  ACS Chemical Biology

• Publication date

  2009-10-16

• Fields of study

  Biology, Medicine, Chemistry

• Identifiers
  DOI 10.1021/cb900143aPMID 19645433PMCID PMC2763043
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Ligand competition binding assay for the androgen receptor.

  2011cited by this paper
• Quantification of the vitamin D receptor-coregulator interaction.

  2009cited by this paper
• A High-Throughput Ligand Competition Binding Assay for the Androgen Receptor and Other Nuclear Receptors

  2009cited by this paper
• Selective androgen receptor modulators in preclinical and clinical development

  2008cited by this paper
• Expanding the therapeutic use of androgens via selective androgen receptor modulators (SARMs).

  2007cited by this paper
• Discovery of antiandrogen activity of nonsteroidal scaffolds of marketed drugs

  2007cited by this paper
• The immunophilin ligands cyclosporin A and FK506 suppress prostate cancer cell growth by androgen receptor-dependent and -independent mechanisms.

  2007cited by this paper
• A surface on the androgen receptor that allosterically regulates coactivator binding

  2007cited by this paper
• Current industrial practices of assessing permeability and P-glycoprotein interaction

  2006influential reference
• Androgen receptor corepressors and prostate cancer.

  2006cited by this paper
• A High-Throughput Screening Method to Identify Small Molecule Inhibitors of Thyroid Hormone Receptor Coactivator Binding

  2006cited by this paper
• The Molecular Mechanisms of Coactivator Utilization in Ligand-dependent Transactivation by the Androgen Receptor*

  2005cited by this paper
• Androgen mediated regulation and functional implications of fkbp51 expression in prostate cancer.

  2005cited by this paper
• Androgen receptor modifications in prostate cancer cells upon long‐termandrogen ablation and antiandrogen treatment

  2005cited by this paper
• Development of Nonsteroidal Anti-Inflammatory Drug Analogs and Steroid Carboxylates Selective for Human Aldo-Keto Reductase Isoforms: Potential Antineoplastic Agents That Work Independently of Cyclooxygenase Isozymes

  2005cited by this paper
• Biology of progressive, castration-resistant prostate cancer: directed therapies targeting the androgen-receptor signaling axis.

  2005cited by this paper
• Combined androgen blockade: the case for bicalutamide.

  2005cited by this paper
• Identification of Genetic Pathways Activated by the Androgen Receptor during the Induction of Proliferation in the Ventral Prostate Gland*

  2004cited by this paper
• The androgen receptor gene mutations database (ARDB): 2004 update

  2004cited by this paper
• The androgen receptor gene mutations database (ARDB): 2004 update

  2004cited by this paper
• Activation functions 1 and 2 of nuclear receptors: molecular strategies for transcriptional activation.

  2003cited by this paper
• Human cytosolic 3alpha-hydroxysteroid dehydrogenases of the aldo-keto reductase superfamily display significant 3beta-hydroxysteroid dehydrogenase activity: implications for steroid hormone metabolism and action.

  2003cited by this paper
• Transcriptional programs activated by exposure of human prostate cancer cells to androgen

  2002cited by this paper
• Combinatorial Control of Gene Expression by Nuclear Receptors and Coregulators

  2002cited by this paper
• Androgens and androgen receptor : mechanisms, functions, and clinical applications

  2002influential reference
• A novel cell line, MDA-kb2, that stably expresses an androgen- and glucocorticoid-responsive reporter for the detection of hormone receptor agonists and antagonists.

  2002cited by this paper
• The program of androgen-responsive genes in neoplastic prostate epithelium

  2002cited by this paper
• Minireview: Nuclear Receptor Coactivators-An Update.

  2002cited by this paper
• Combinatorial control of gene expression by nuclear receptors and coregulators.

  2002cited by this paper
• Molecular biology of the androgen receptor.

  2002cited by this paper
• Functional dissection of transcriptional profiles in androgen-dependent and -independent prostate cancer

  2001cited by this paper
• Mutations at the boundary of the hinge and ligand binding domain of the androgen receptor confer increased transactivation function.

  2001cited by this paper
• Dysregulated expression of androgen-responsive and nonresponsive genes in the androgen-independent prostate cancer xenograft model CWR22-R1.

  2000cited by this paper
• An update on bicalutamide in the treatment of prostate cancer.

  1999cited by this paper
• A nonsteroidal anti-inflammatory drug, flufenamic acid, inhibits the expression of the androgen receptor in LNCaP cells.

  1999cited by this paper
• Functional interactions of the AF-2 activation domain core region of the human androgen receptor with the amino-terminal domain and with the transcriptional coactivator TIF2 (transcriptional intermediary factor2).

  1998cited by this paper
• The nuclear receptor superfamily: the second decade.

  1995cited by this paper
• The androgen receptor gene mutations database.

  1994cited by this paper
• Androgen receptor phosphorylation, turnover, nuclear transport, and transcriptional activation. Specificity for steroids and antihormones.

  1992cited by this paper
• Blockers of platelet-derived growth factor-activated nonselective cation channel inhibit cell proliferation.

  1992cited by this paper
• Additions and Corrections -ρ-σ-πAnalysis. A Method for the Correlation of Biological Activity and Chemical Structure.

  1964cited by this paper
• p-σ-π Analysis. A Method for the Correlation of Biological Activity and Chemical Structure

  1964cited by this paper

• Homoeriodictyol, targeting the bitter taste receptor TAS2R14, lowers the secretion of pro-inflammatory chemokines upon treatment with SARS-CoV-2 peptide pools in human peripheral blood mononuclear cells.

  2026cites this paper
• The Relationship between AKR1C3 and Diseases

  2025cites this paper
• Prognostic role of TEAD4 in TNBC: in-silico inhibition of the TEAD4-YAP interaction by flufenamic acid analogs

  2024cites this paper
• Fenamates: Forgotten treasure for cancer treatment and prevention: Mechanisms of action, structural modification, and bright future

  2024cites this paper
• Development of LM98, a Small‐Molecule TEAD Inhibitor Derived from Flufenamic Acid

  2021cites this paper
• Overview of AKR1C3: Inhibitor Achievements and Disease Insights.

  2020cites this paper
• Targeting Vitamin-D receptor (VDR) by a small molecule antagonist MeTC7 inhibits PD-L1 but controls THMYCN neuroblastoma growth PD-L1 independently

  2020cites this paper
• Dual Inhibitory Action of a Novel AKR1C3 Inhibitor on Both Full-Length AR and the Variant AR-V7 in Enzalutamide Resistant Metastatic Castration Resistant Prostate Cancer

  2020cites this paper
• Flufenamic acid alleviates sepsis‐induced lung injury by up‐regulating CBR1

  2020cites this paper
• Rational design of agonists for bitter taste receptor TAS2R14: from modeling to bench and back

  2019cites this paper
• Non-Steroidal Androgen Receptor Antagonists and Prostate Cancer: a Survey on Chemical Structures Binding this Fast-Mutating Target.

  2019cites this paper
• Androgen-regulation of sepsis response : beneficial role of androgen receptor antagonists

  2015cites this paper
• In Silico Functional Pathway Annotation of 86 Established Prostate Cancer Risk Variants

  2015cites this paper
• Synthesis and evaluation of methylsulfonylnitrobenzamides (MSNBAs) as inhibitors of the thyroid hormone receptor-coactivator interaction.

  2013cites this paper
• Structure–activity relationship studies of miniproteins targeting the androgen receptor–coactivator interaction

  2013cites this paper
• AKR1C3 as a target in castrate resistant prostate cancer.

  2013cites this paper
• Targeting the binding function 3 (BF3) site of the androgen receptor through virtual screening. 2. development of 2-((2-phenoxyethyl) thio)-1H-benzimidazole derivatives.

  2013cites this paper
• Crystal structures of AKR1C3 containing an N-(aryl)amino-benzoate inhibitor and a bifunctional AKR1C3 inhibitor and androgen receptor antagonist. Therapeutic leads for castrate resistant prostate cancer.

  2012cites this paper
• Efficacy of a Non-Hypercalcemic Vitamin-D2 Derived Anti-Cancer Agent (MT19c) and Inhibition of Fatty Acid Synthesis in an Ovarian Cancer Xenograft Model

  2012cites this paper
• Synthesis and evaluation of sulfonylnitrophenylthiazoles (SNPTs) as thyroid hormone receptor-coactivator interaction inhibitors.

  2012cites this paper
• Methylsulfonylnitrobenzoates, a New Class of Irreversible Inhibitors of the Interaction of the Thyroid Hormone Receptor and Its Obligate Coactivators That Functionally Antagonizes Thyroid Hormone*

  2011cites this paper
• Identification and characterization of FKBP52-specific inhibitors for the treatment of prostate cancer

  2011cites this paper
• Developments in Nonsteroidal Antiandrogens Targeting the Androgen Receptor

  2010cites this paper
• Minireview: Not picking pockets: nuclear receptor alternate-site modulators (NRAMs).

  2010cites this paper
• Transcriptional Switches: Chemical Approaches to Gene Regulation*

  2010cites this paper
• New frontiers in androgen biosynthesis and metabolism

  2010cites this paper